Predicted to enable cytoskeletal protein binding activity. Predicted to be involved in several processes, including actomyosin structure organization; positive regulation of keratinocyte migration; and wound healing. Predicted to be located in apical part of cell; cytosol; and plasma membrane. Predicted to be active in cytoskeleton. Orthologous to human EPB41L4B (erythrocyte membrane protein band 4.1 like 4B); INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 2,2',4,4'-Tetrabromodiphenyl ether.
[Estradiol co-treated with Progesterone] results in increased expression of EPB41L4B mRNA and [Estradiol co-treated with TGFB1 protein] results in decreased expression of EPB41L4B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA
[bisphenol A co-treated with Fulvestrant] results in increased methylation of EPB41L4B gene and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA
[perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of EPB41L4B mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of EPB41L4B mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA